ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer.

被引：1
|
作者：
Bouzyk, M.
Gray, K. P.
Regan, M. M.
Pagani, O.
Tang, W.
Kammler, R.
Maibach, R.
Viale, G.
Dell'Orto, P.
Thurlimann, B. J. K.
Hitre, E.
Lyng, M.
Ditzel, H. J.
Neven, P.
MacGrogan, G.
Price, K. N.
Gelber, R. D.
Coates, A. S.
Goldhirsch, A.
Leyland-Jones, B.
机构：
[1] Emory Univ, Sch Med, Atlanta, GA USA
[2] IBCSG Stat Ctr, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Inst Oncol Southern Switzerland, Lugano Viganello, Switzerland
[5] Emory Biomarker Serv Ctr, Atlanta, GA USA
[6] IBCSG Cent Pathol Off, Milan, Italy
[7] IBCSG Coordinating Ctr, Bern, Switzerland
[8] European Inst Oncol, Milan, Italy
[9] Kantonsspital, St Gallen, Switzerland
[10] Natl Inst Oncol, Budapest, Hungary
[11] Univ Southern Denmark, Odense, Denmark
[12] Odense Univ Hosp, DK-5000 Odense, Denmark
[13] UZ Leuven, Louvain, Belgium
[14] Inst Bergonie, Bordeaux, France
[15] Univ Sydney, Sydney, NSW 2006, Australia
[16] Emory Univ, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.1002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1002
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Microsatellites in the Estrogen Receptor (ESR1, ESR2) and Androgen Receptor (AR) Genes and Breast Cancer Risk in African American and Nigerian Women
    Zheng, Yonglan
    Huo, Dezheng
    Zhang, Jing
    Yoshimatsu, Toshio F.
    Niu, Qun
    Olopade, Olufunmilayo I.
    PLOS ONE, 2012, 7 (07):
  • [42] Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer
    Rasmussen, Birgitte B.
    Ejlertsen, Bent
    Nielsen, Kirsten Vang
    Balslev, Eva
    Muller, Sven
    Moller, Susanne
    Mouridsen, Henning T.
    APMIS, 2008, 116 (03) : 248 - 249
  • [43] Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer
    Kirsten Vang Nielsen
    Bent Ejlertsen
    Sven Müller
    Susanne Møller
    Birgitte B. Rasmussen
    Eva Balslev
    Anne-Vibeke Lænkholm
    Peer Christiansen
    Henning T. Mouridsen
    Breast Cancer Research and Treatment, 2011, 127 : 345 - 355
  • [44] Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer
    Nielsen, Kirsten Vang
    Ejlertsen, Bent
    Muller, Sven
    Moller, Susanne
    Rasmussen, Birgitte B.
    Balslev, Eva
    Laenkholm, Anne-Vibeke
    Christiansen, Peer
    Mouridsen, Henning T.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (02) : 345 - 355
  • [45] Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer
    Ejlertsen, B.
    Nielsen, K., V
    Rasmussen, B. B.
    Balslev, E.
    Muller, S.
    Moller, S.
    Mouridsen, H. T.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S34 - S34
  • [46] COST-EFFECTIVENESS OF LETROZOLE AND OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER USING UPDATED SURVIVAL DATA FROM THE BIG 1-98 AND ATAC TRIALS: A UK PERSPECTIVE
    Karnon, J.
    Kaura, S.
    VALUE IN HEALTH, 2010, 13 (07) : A264 - A264
  • [47] Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer:: supplementary results from the BIG 1-98 randomised trial
    Rasmussen, Birgitte B.
    Regan, Meredith M.
    Lykkesfeldt, Anne E.
    Dell'Orto, Patrizia
    Del Curto, Barbara
    Henriksen, Katrine L.
    Mastropasqua, Mauro G.
    Price, Karen N.
    Mery, Eliane
    Lacroix-Triki, Magali
    Braye, Stephen
    Altermatt, Hans J.
    Gelber, Richard D.
    Castiglione-Gertsch, Monica
    Goldhirsch, Aron
    Gusterson, Barry A.
    Thurlimann, Beat
    Coates, Alan S.
    Viale, Giuseppe
    LANCET ONCOLOGY, 2008, 9 (01): : 23 - 28
  • [48] Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
    Regan, Meredith M.
    Price, Karen N.
    Giobbie-Hurder, Anita
    Thuerlimann, Beat
    Gelber, Richard D.
    BREAST CANCER RESEARCH, 2011, 13 (03)
  • [49] Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
    Meredith M Regan
    Karen N Price
    Anita Giobbie-Hurder
    Beat Thürlimann
    Richard D Gelber
    Breast Cancer Research, 13
  • [50] Central assessment of ER, PgR and HER2 in BIG 1-98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer
    Rasmussen, B. B.
    Regan, M. M.
    Lykkesfeldt, A. E.
    Dell'Orto, P.
    Del Curto, B.
    Henriksen, K. L.
    Mastropasqua, M. G.
    Thurlimann, B.
    Viale, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345